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ABSTRACT
Objective: We performed a systematic review and meta-analyses to assess the evidence for ge-
netic associations with brain microbleeds (BMBs).
Methods:We sought all published studies of the association between any genetic polymorphism and
BMBs studied in a total of100 people. We critically appraised studies, and calculated pooled odds
ratios (ORs) using the generic inverse variance fixed effects method. We used I2 and 2 statistics to
assess heterogeneity, and fail-safe N estimates to assess the robustness of our results.
Results: Only the APOE 2/3/4 polymorphism had been studied in 100 people (10 studies,
7,351 participants). Comparedwith people with the 3/3 genotype, carriers of the 4 allele (4)
were statistically significantly more likely to have BMBs in any location (4 vs 3/3: pooled OR
1.22, 95% confidence interval [CI] 1.05–1.41, p  0.01). For strictly lobar BMBs, this associa-
tion appeared slightly stronger (4 vs 3/3: pooled OR 1.35, 95% CI 1.10–1.66, p  0.005).
The association of 4 genotypes with strictly lobar BMBs was reasonably robust to potential
publication and reporting biases.
Conclusions: Given the known associations of APOE alleles with lobar intracerebral hemorrhage
and cerebral amyloid angiopathy, these findings support the concept that strictly lobar BMBsmay
be an imaging biomarker of cerebral amyloid angiopathy. Neurology® 2011;77:158–167
GLOSSARY
BMB  brain microbleed; CAA  cerebral amyloid angiopathy; CI  confidence interval; GRE  gradient-recalled echo;
HWE Hardy-Weinberg equilibrium; ICH intracerebral hemorrhage; OR odds ratio.
Brain microbleeds (BMBs) are minute deposits of blood products, seen as focal areas of signal
loss typically 10 mm in diameter on haem-sensitive T2*-weighted gradient-recalled echo
(GRE) MRI sequences. BMBs occur in 5% to 38% of apparently healthy people, increasing in
frequency with age, hypertension, and smoking.1-3 They are particularly prevalent (50%) in
people with a history of intracerebral hemorrhage (ICH).1 Lobar BMBs are considered a diag-
nostic marker of cerebral amyloid angiopathy (CAA),4 which appears to be the major cause of
lobar, sometimes recurrent ICH in the elderly.5
Understanding the vascular pathology underlying BMBs should be enhanced by identifying
genetic risk factors. There is particular interest in whether APOE genotype might confer sus-
ceptibility to BMBs. The APOE gene on chromosome 19 has 3 common alleles—2, 3, and
4—giving rise to 6 different genotypes: 2/2, 2/3, 2/4, 3/3 (the wild type, occurring in
just under two-thirds of people in most populations6), 3/4, and 4/4. Associations of the
APOE 2 or 4 alleles with both ICH (particularly lobar ICH) and CAA have been described,7-11
and strictly lobar BMBs have now been included in the modified Boston diagnostic criteria for
CAA.4Wewould therefore expect an association between these alleles and BMBs, especially those in
a strictly lobar location.
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We therefore carried out a systematic review
of the literature on genetic variants associated
with BMBs and, where appropriate, meta-
analyses of the relationship between polymor-
phisms in any gene (including APOE) and
BMBs.
METHODS Search strategy and selection criteria. We
sought articles published in full in any language, obtaining trans-
lations where necessary, which studied an association between
any genetic polymorphism and BMBs detected on MRI in hu-
mans. We used comprehensive electronic search strategies (most
recent search date July 2010) including a list of 13 different
medical subject heading and text word terms for BMBs and 13
and 17 different medical subject heading and text word terms for
genes or polymorphisms in Medline (from 1966) and Embase
(from 1980) respectively to identify relevant articles (appendix).
Two authors (S.S.M. and L.P.) read the titles, abstracts, and,
where necessary, full text of all identified studies to identify po-
tentially relevant studies, resolving any uncertainties with a third
author (C.L.M.S.). At least 2 authors (S.S.M. and one or both of
C.A.J. and C.L.M.S.) read in full all articles selected as poten-
tially relevant and, for each genetic polymorphism, determined
the number of independent studies and the total number of par-
ticipants included. Two authors (S.S.M. and L.P.) hand-
searched the reference lists of all included studies and any related
review articles to identify relevant studies missed in the initial
search. Where a polymorphism had been studied in a total of
100 participants, we selected the relevant studies for detailed
methodologic assessment and meta-analyses. We decided not to
review data for polymorphisms studied in 100 participants
since conclusions drawn on the basis of such small numbers
would be likely to be unreliable.
Data extraction. For each selected study, we extracted infor-
mation on year of publication; country in which the study was
conducted; types of participants studied; number, ethnicity, and
mean age of participants; genotyping method; whether geno-
types were stated to be in Hardy-Weinberg equilibrium (HWE);
and blinding of scanning staff to genotypes and of genotyping
staff to scan results. We also extracted information on the quality
and features of the brain imaging methods used. These included
the criteria specified to identify a BMB (both appearance and
size), the awareness of potential BMBmimics, the MRI sequence
used, the number of MRI scan readers, and any available data on
interobserver and intraobserver agreement of BMB rating. We
assessed each study against a checklist of key quality indicators
(clearly defined BMB criteria, awareness of 2 BMB mimics,
2 BMBs raters, raters independent, interobserver and intraob-
server agreement recorded, genotypes stated to be in HWE,
blinding of BMB raters to genotype and genotyping staff to
BMB status, adjustment of results for other risk factors) that we
developed from the above methodologic, imaging, and labora-
tory criteria and with reference to both the Strengthening the
Reporting of Genetic Association Studies statement12 and the
ideal characteristics for a study of BMBs.1 However, we did not
include or exclude studies on the basis of these quality indicators.
Two authors (S.S.M. and C.A.J.) independently extracted
published data from each study on the number of participants
with at least one BMB for each genotype or group of genotypes,
or published crude or adjusted odds ratios (ORs) derived from
these data. S.S.M. and C.A.J. discussed and resolved any dis-
agreements with a third author (C.L.M.S.). For APOE studies,
where possible, we subdivided the participants into those with an
2-containing (2), 4-containing (4), or 3/3 genotype,
and excluded the small proportion with 2/4 genotypes, allow-
ing the most consistent treatment of data across studies. Where
available, we extracted data on the relationship between APOE
and BMBs in either strictly lobar or not strictly lobar distribu-
tions, assigning participants with BMBs restricted to a lobar lo-
cation to the strictly lobar group and all others with BMBs to the
not strictly lobar group. If studies had not published these data,
we approached the corresponding author for additional unpub-
lished data on location-specific BMB-genotype associations in an
effort to include all available data in our meta-analyses. If the
same participants had been included in more than one publica-
tion, we only included those from the publication with the larger
number of participants.
Statistical analysis. We performed meta-analyses using Co-
chrane RevMan (version 4.2) software. We describe here meth-
ods used for analyses of the APOE 2/3/4 polymorphism since
this turned out to be the only polymorphism studied in 100
participants. Where studies provided the necessary data, we cal-
culated directly study-specific ORs for the presence vs absence of
BMBs, comparing participants with an 2 or 4 genotype vs
the 3/3 genotype, and otherwise used the relevant published
crude or adjusted ORs. We used the generic inverse variance
fixed effect meta-analysis method to obtain pooled ORs, weight-
ing each study by the inverse of the square of the standard error
of its study-specific OR. Where both crude and adjusted ORs
were available for a particular study, we used the crude OR for
meta-analysis, and compared the crude and adjusted ORs to as-
sess for the possibility of confounding. Unless stated otherwise,
we considered a p value of 0.05 to be statistically significant.
We assessed statistical heterogeneity between studies using
both the 2 test and the I2 statistic.13 We performed prespecified
subgroup analyses based on study size (above or below the mean
study size), ethnicity, and type of study population (healthy indi-
viduals compared with those recruited on the basis of existing
neurologic conditions), to explore potential modification of ef-
fect by these factors, assessing differences between subgroups
with 2 statistics. We also assessed the effects of genotype on
strictly lobar and not strictly lobar BMBs separately.
To assess the potential effect on our results of unpublished
negative studies or studies not reporting or able to provide the
data required for our meta-analyses (i.e., the potential for publi-
cation and reporting biases), we calculated the “fail-safe N” for
any meta-analysis which produced a significant result (p 
0.05). We used a modification of Rosenthal’s method,14 in which
we determined the size of a notional study with a null result
(OR  1) required to bring any significant result to a just non-
significant level (p  0.05), assuming the overall prevalence of
BMBs and the distribution of genotypes in this notional study to
be the average of these for the studies included. Since we carried
out several tests of significance, we repeated our fail-safe N calcu-
lations based on a statistical significance cutoff of p  0.01.
We prepared this report with reference to the Meta-analysis
of Observational Studies in Epidemiology reporting guidelines.15
RESULTS We identified 112 articles in our initial
search of Medline and Embase, of which 31 were
potentially relevant to this systematic review. Only
the APOE 2/3/4 polymorphism had been studied in
a total of100 participants. Ten studies assessed the
association between APOE 2/3/4 genotypes and
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BMBs in a total of 7,351 participants (figure 1).
Seven studies which included 7,272 participants
(99% of the total) presented dichotomous data for
BMBs (i.e., presence vs absence per genotype or
group of genotypes), enabling their results to be
pooled in meta-analyses.2,3,16-21 The remaining 3 pre-
sented continuous data (i.e., mean number of BMBs
per genotype) or purely qualitative statements about
the association between APOE and BMBs.22-24
Study characteristics. Study populations comprised ei-
ther healthy people from the general population (3
studies, 5,977 participants) or those with neurologic
(mainly cerebrovascular) conditions (7 studies, 1,374
participants). Most participants were of European ori-
gin, but one study was conducted in Asians.17 Partici-
pants were middle-aged to elderly (mean age per study
ranged from 45 to 76 years). Studies had a mean of 735
(range 20 to 3,689) participants. Prevalence of BMBs in
the study populations varied from 5% in the Framing-
ham and Framingham offspring population-based co-
hort to 65% in a population of people hospitalized with
intracerebral hemorrhage (table 1).
Imaging characteristics varied between the studies.
BMBs were typically defined as rounded focal areas of
signal loss, but the size criteria varied. All studies but
one17 considered BMBmimics, most commonly calcifi-
cation in the basal ganglia (although none of the studies
appeared to use CT to investigate this) (table e-1 on the
Neurology® Web site at www.neurology.org). The
larger studies generally fulfilled more of our quality in-
dicators for a study on BMB genetics than smaller stud-
ies, but none fulfilled all 10 (table 2). The studies with
Figure 1 Study selection and exclusion
BMB  brain microbleed; CADASIL  cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy.
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data unavailable or unsuitable for our meta-analyses
were much smaller in size than the included studies and
performed less well against our methodologic quality
indicators (table 2).22-24 The largest study was of high
quality and contributed over half of the participants in-
cluded in the meta-analyses.3,21 Where both crude and
adjusted ORs were available, they were similar.17,20
Association between APOE 2/3/4 polymorphism and
BMBs. In the 7 studies with dichotomous data on
BMBs, pooled results showed that, compared with
people with an 3/3 genotype, those with an 4
genotype had an increased odds of having one or
more BMBs (OR 1.22, 95% confidence interval [CI]
1.05–1.41, p  0.01; figure 2A). There was no dif-
ference between the odds of having BMBs among
those with an 2 vs those with an e3/3 genotype
(OR 1.14, 95% CI 0.94–1.40, p  0.2; figure 3A).
There was no evidence from 2 or I2 statistics of any
heterogeneity between the studies’ results for either
of these genotype group comparisons (figures 2A and
3A), and there were no differences between the
pooled results of studies divided into subgroups ac-
cording to study size, ethnicity, or type of study pop-
ulation (data not shown).
Two studies had published sufficient data for in-
clusion in our meta-analyses of the association be-
tween APOE genotypes and strictly lobar vs not
strictly lobar BMBs.3,17,21 We sought additional un-
published data from 3 other studies that had not in-
cluded them in their publications, of which 2
provided them,18,20 and one did not.2 The 4 studies
with location-specific data available included 4,883
(66%) of all 7,351 participants. The association be-
tween 4 genotypes and BMBs was slightly stron-
ger and more significant for participants with BMBs
in a strictly lobar location vs those with no BMBs
Table 1 Characteristics of included studies
Study references Types of participants
Total study
populationa/no.
scanned and
genotyped/no. of
these with BMBsb Country Ethnicityc %Maled
Mean
age, yd
Studies included
in meta-analysis
16 Population-based; participants from the Framingham
original and offspring cohorts
472/368/17b USA Mostly white 45e 61e
17 Patients with “neurologic abnormalities” (70% stroke
or TIA, others vertigo, headache, parkinsonism,
dementia) requiring MRI
414/414/117 Korea Korean 52 66
18 Memory clinic patients attending a Dutch university
Alzheimer center 2002–2005
772/438/62 Netherlands Assumed white/
Dutch
53e 66e
19 Patients admitted to a German teaching hospital
with nontraumatic primary ICH, 1997–2000
193/101/65b Austria Central European NR 68e
20 Patients50 years with TIA or ischemic stroke
admitted to hospital, 2003–2005
342/342/89 Belgium Assumed white/
Belgian
62 71
2 Population-based; participants born in Reykjavik
1907–1935 who participated in the Reykjavik study
in 1967 and survived to be reexamined in 2002
1,962/1,920/214 Iceland Assumed white/
Icelandic
42e 76e
3, 21 Population-based; participants living in Rotterdam 3,979/3,689/565 Netherlands Assumed white/
Dutch
46e 60e
Studies with
missing or
incompatible data
not included in
meta-analysis
22 DNA-proven HCHWA-Dmutation carriers 27/20/13b Netherlands Assumed white/
Dutch
52e 49e
24 DNA-confirmed CADASIL NOTCH 3 mutation
carriers
36/36/? Netherlands Assumed white/
Dutch
47 45
23 Patients with primary ICH who fulfilled their criteria
for CAA (1: age55 y; 2: lobar primary ICH with
exclusion of other causes)
50/23/19 Portugal Assumed white/
Portuguese
50e 72e
Abbreviations: BMB  brain microbleed; CAA  cerebral amyloid angiopathy; CADASIL  cerebral autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy; HCHWA-D  Hereditary Cerebral Haemorrhage with Amyloidosis–Dutch type; ICH  intracerebral hemorrhage; NR 
not reported.
a As described under “types of participants.”
b Estimated from published%where necessary, as marked.
c Assumed indicates ethnicity not directly stated.
d Of number of participants scanned and genotyped, unless stated otherwise.
e Mean age and%male of total study population.
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(OR 1.35, 95% CI 1.10–1.66, p  0.005), while it
was slightly weaker and nonsignificant for those with
not strictly lobar BMBs vs those with no BMBs (OR
1.16, 95% CI 0.89–1.50) (figure 2B). We could not
carry out a formal significance test for the difference
between these results for strictly lobar and not strictly
lobar BMBs since both used the same no BMBs com-
parison group. However, we noted the 95% CIs for
these results to be overlapping. There was no associa-
tion of 2 genotypes with either strictly lobar or
not strictly lobar BMBs (OR for strictly lobar BMBs
1.20, 95% CI 0.92–1.57, p  0.2; OR for not
strictly lobar BMBs 1.03, 95 CI 0.73–1.46, p 0.9)
(figure 3B).
Of the studies not contributing data to the meta-
analyses of APOE associations with BMBs in strictly
lobar vs not strictly lobar locations, 2 studies (between
them including 469 participants) mentioned that they
did not find an association of APOE genotype with lo-
bar BMBs.15,18 However, one study including 1,920
participants with data on APOE genotype and BMB
location did not comment on the associations of APOE
genotypes with BMBs by location and was unable to
provide these unpublished data for inclusion in our
location-specific meta-analyses.2 Fail-safe N calculations
showed that it would require null studies of around
7,700 and 4,800 participants respectively to bring the
associations of 4 genotypes with any BMBs and with
strictly lobar BMBs to a just statistically nonsignificant
level (i.e., p 0.05).When we set the cutoff for statisti-
cal significance at p 0.01, the association of 4 ge-
notypes with any BMBs became of borderline
significance only while the fail-safe N study size for the
association with strictly lobar BMBs was around 940
participants.
DISCUSSION Our systematic review and meta-
analyses of genetic associations with BMBs suggest
that 4 APOE allele carriers are at higher risk of hav-
ing BMBs, particularly in strictly lobar brain loca-
tions. Our data would also be compatible with an
association between 2 genotypes and strictly lobar
BMBs but this could only be considered speculative,
since this association was not significant in our anal-
yses. Given the reported associations of APOE geno-
type with CAA and lobar intracerebral hemorrhage,
our data support strictly lobar BMBs as a possible
imaging biomarker of CAA.7,8,10,25 APOE 4 and 2
alleles may increase the risk of developing cerebral
small cortical vessel fragility and consequent leakage
of tiny amounts of blood particularly within the lo-
bar regions, because patients who had lobar ICH and
carried either of these alleles developed new BMBs at
increased frequency compared to 3/3 allele carri-
ers.26 Several animal studies have shown that APOE
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4 glycoprotein product enhances deposition of
-amyloid peptide within the vessels causing smooth
muscle loss and vessel wall thickening with an in-
creased risk of vessel leakage.27 The 2 allele has been
demonstrated to increase fibrinoid necrosis of amy-
loid laden vessels, and to be associated with an in-
Figure 2 Meta-analysis of the association between 4 vs 3/3 genotypes and brain microbleeds (BMBs)
(A) BMBs in any location. (B) BMBs in strictly lobar or not strictly lobar locations. Studies are displayed in order of publication
date. The squares represent study-specific odds ratios (ORs), with their size proportional to their statistical weight by the ge-
neric inverse variancemethod. Horizontal lines represent 95%confidence intervals (CIs). Diamonds represent pooledORs, and
their width represents the 95% CI for the relevant pooled OR. *Number of participants included in analysis. For some studies,
where numbers of participants per genotypewere not provided,we estimated the total number of participantswith 4 or 3/3
genotypes, assuming the distribution of the genotypes to be the average of the included studies with available data on each
genotype. This provides a rough estimate of numbers of participants included in the comparison, but has no effect on the study-
specific OR, standard error, ormeta-analysis calculations. **Study used slightly different comparison groups (4 vs 4).
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creased incidence of newly developed BMBs on
follow-up scans.28,29
By its restriction to fully published studies, our
systematic review is potentially subject to publication
bias.30 Furthermore, although we sought some addi-
tional unpublished data, only 4 studies in around
two-thirds of the total number of participants from
relevant studies contributed data on the association
Figure 3 Meta-analysis of the association between 2 vs 3/3 genotypes and brain microbleeds (BMBs)
(A) BMBs in any location. (B) BMBs in strictly lobar or not strictly lobar locations. Notation as for figure 2. *Number of
participants included in analysis. For some studies, where numbers of participants per genotype were not provided, we
estimated the total number of participants with 2 or 3/3 genotypes, assuming the distribution of the genotypes to be
the average of the included studies with available data on each genotype. This provides a rough estimate of numbers of
participants included in the comparison, but has no effect on the study-specific OR, standard error, or meta-analysis calcu-
lations. **Study used slightly different comparison groups (2 vs 2). CI confidence interval.
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between APOE polymorphisms and BMB location.
The results may therefore be subject to reporting bias
(i.e., those studies which found an association be-
tween lobar BMBs and APOE genotype may have
been more likely to report their location-specific
findings). Our fail-safe N calculations would suggest
that a substantial amount of data from a null study or
studies would be required to render nonsignificant
(p  0.05) the demonstrated associations of the 4
allele with BMBs and with strictly lobar BMBs.
However, with a more stringent significance level of
p  0.01 (accounting for multiple testing), the asso-
ciation of 4 genotypes with any BMBs was only
borderline, while the association with strictly lobar
BMBs would become nonsignificant with the ad-
dition to our meta-analysis of a further 940 partic-
ipants with a null result. Since this is not
implausible, we conclude that the demonstrated
4 associations are reasonably robust to the po-
tential effects of publication and reporting bias,
but not completely secure.
Although variation in imaging characteristics be-
tween studies may have led to a variation in the size
of associations detected between genotype and
BMBs, we did not detect any such heterogeneity.
None of the studies included in our review fulfilled
all our methodologic quality indicators for a study on
the association between genotype and BMBs. En-
couragingly, however, the larger studies which pro-
vided the most weight in the meta-analyses performed
better against our quality indicators, increasing confi-
dence in the overall pooled OR. Furthermore, a low-
quality score does not necessarily indicate a poor
quality study but one for which important methodo-
logic quality indicators are incompletely reported.
The results of our meta-analyses depend critically on
the inclusion of the largest study which contributed
over half of the participants. Reassuringly, this study
was of high quality.3,21
A further limitation of our study is that analyses
for APOE used a dominant genetic model, while it
seems likely that an additive model would be both
biologically more accurate and statistically somewhat
more powerful, and may have improved our ability
to detect a significant association with the APOE 2
allele.11,21 However, since our analyses relied mainly
on the availability of published data, we had to use
the dominant model used in the publications. While
an individual participant data meta-analysis with in-
clusion of unpublished data from all studies would
have allowed us to analyze the data more flexibly
with an additive genetic model, it would have re-
quired considerably more time and resources, and
may well have been possible only for a more limited
dataset.
We have therefore demonstrated an association
between 4-containing APOE genotypes and BMBs,
and have shown that the association with strictly lo-
bar BMBs is reasonably robust. Future studies in this
area would be improved by the use of a consistent
definition of BMBs5 and a robust method of rating
BMBs, such as the Brain Observer Microbleed
Scale31 or Microbleed Anatomic Rating Scale,32 to
improve the comparability of different studies and
facilitate future meta-analyses. The statistical power
of future studies may be improved by treating BMBs
as a continuous or at least ordered categorical vari-
able, rather than as a dichotomous variable, as the
majority of studies (and so our meta-analyses) have
up to now. While only the APOE genotype has been
studied in large numbers of people so far within the
published literature, genome-wide association studies
may soon be able to identify other, similarly impor-
tant genes.
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